Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ACXP

ACXP - Acurx Pharmaceuticals, Inc. Stock Price, Fair Value and News

3.01USD+0.14 (+4.88%)Market Closed
Watchlist

Market Summary

USD3.01+0.14
Market Closed
4.88%

ACXP Stock Price

View Fullscreen

ACXP RSI Chart

ACXP Valuation

Market Cap

41.4M

Price/Earnings (Trailing)

-3.26

Price/Free Cashflow

-5.84

ACXP Price/Earnings (Trailing)

ACXP Profitability

Return on Equity

-323.37%

Return on Assets

-135.69%

Free Cashflow Yield

-17.13%

ACXP Fundamentals

ACXP Earnings

Earnings (TTM)

-12.7M

Earnings Growth (Yr)

12.05%

Earnings Growth (Qtr)

9.59%

Breaking Down ACXP Revenue

Last 7 days

12.2%

Last 30 days

-30.4%

Last 90 days

-13.0%

Trailing 12 Months

-8%

How does ACXP drawdown profile look like?

ACXP Financial Health

Current Ratio

2.22

ACXP Investor Care

Shares Dilution (1Y)

18.77%

Diluted EPS (TTM)

-1.05

Tracking the Latest Insider Buys and Sells of Acurx Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 19, 2024
sailer carl
acquired
70,066
3.55
19,737
-
Jan 03, 2024
deluccia robert j
acquired
70,066
3.55
19,737
-
Jan 03, 2024
luci david p
acquired
70,066
3.55
19,737
president and ceo
Dec 22, 2023
deluccia robert j
gifted
-
-
-30,000
-
Dec 12, 2023
deluccia robert j
gifted
-
-
-40,000
-
Jul 27, 2022
deluccia robert j
bought
75,000
3.8
19,737
-
Jul 27, 2022
luci david p
bought
75,000
3.8
19,737
president and ceo
Jul 27, 2022
sailer carl
bought
75,000
3.8
19,737
-
Dec 02, 2021
deluccia robert j
gifted
-
-
-40,000
-
Nov 23, 2021
sailer carl
bought
24,979
4.84
5,161
-

1–10 of 13

Which funds bought or sold ACXP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Prospect Financial Services LLC
new
-
977,225
977,225
0.99%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
205,108
205,108
-%
Feb 14, 2024
CITADEL ADVISORS LLC
reduced
-27.3
25,517
52,460
-%
Feb 14, 2024
Royal Bank of Canada
added
70.97
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
235
1,374,600
1,556,460
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-20,841
-
-%
Feb 14, 2024
LPL Financial LLC
new
-
52,394
52,394
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-15,158
-
-%
Feb 14, 2024
Semmax Financial Advisors Inc.
unchanged
-
-4,115
16,460
0.01%

1–10 of 33

Are Funds Buying or Selling ACXP?

Are funds buying ACXP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACXP
No. of Funds

Unveiling Acurx Pharmaceuticals, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
4.99%
723,104
SC 13G/A
Feb 14, 2023
armistice capital, llc
7.59%
880,000
SC 13G
Feb 14, 2023
armistice capital, llc
9.99%
2,997,111
SC 13G

Recent SEC filings of Acurx Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
4
Insider Trading
Jan 04, 2024
4
Insider Trading
Jan 04, 2024
4
Insider Trading

Peers (Alternatives to Acurx Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.3B
6.8B
-16.59% -47.80%
-7.7
5.3
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
-23.99% -31.71%
-43.66
10.51
76.23% 61.08%
16.4B
2.4B
-4.89% -18.90%
98.05
6.79
15.42% 18.43%
13.3B
3.7B
-7.62% -26.87%
22.19
3.59
8.87% 75.42%
MID-CAP
7.7B
396.6M
-2.06% 34.31%
-14.57
19.42
425.83% 18.94%
6.3B
-
-3.85% 226.12%
-10.06
60.35
54.84% -25.61%
4.5B
240.7M
-19.08% -10.99%
-15.05
18.56
-1.03% -92.09%
4.0B
726.4M
-12.60% 32.37%
-64.55
5.45
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.3
14.41
440.80% -27.84%
SMALL-CAP
2.0B
398.2M
-3.38% -9.50%
28.08
5.03
85.90% -14.05%
752.9M
983.7M
-9.17% -57.89%
-1.38
0.77
-50.36% 17.16%
217.0M
4.9M
-14.18% -58.18%
-1.32
44.39
-57.57% 50.48%
154.8M
881.7K
289.54% 381.25%
-3.26
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Acurx Pharmaceuticals, Inc. News

Latest updates
Investing.com27 Feb 202412:31 pm

Acurx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets0.6%9,3779,3189,25911,32213,25414,99017,44010,3323,224
  Current Assets-14.3%9,37710,9459,209-13,254----
    Cash Equivalents-14.1%9,11210,6079,09211,08312,95914,45917,0962,6283,175
Liabilities74.4%2,0621,1824746338447121,9191,221522
  Current Liabilities74.4%2,0621,1824746338447121,919-473
Shareholder's Equity-25.1%7,3159,7638,78510,68912,41014,27715,5222,4712,702
  Retained Earnings-9.2%-38,641-35,380-31,838-29,218-26,548-23,921-19,279--13,800
  Additional Paid-In Capital1.8%45,94445,13240,61439,89738,94838,18834,791--
Shares Outstanding10.2%11,62810,55210,24810,23310,21610,1166,9086,8676,191
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations-32.8%-2,093-1,576-1,932-1,495-2,180-1,990-1,876-1,500-2,636-329-547---
  Share Based Compensation3.3%8338067336976977177616732,0712,220192---
Cashflow From Financing-----1*----------

ACXP Income Statement

2023-09-30
CONDENSED INTERIM STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
OPERATING EXPENSES    
Research and Development$ 1,348,985$ 1,591,043$ 4,100,954$ 3,321,623
General and Administrative1,765,9961,950,5515,362,2245,510,642
TOTAL OPERATING EXPENSES3,114,9813,541,5949,463,1788,832,265
NET LOSS$ (3,114,981)$ (3,541,594)$ (9,463,178)$ (8,832,265)
LOSS PER SHARE    
Basic net loss per common share$ (0.24)$ (0.32)$ (0.77)$ (0.84)
Diluted net loss per common share$ (0.24)$ (0.32)$ (0.77)$ (0.84)
Weighted average common shares outstanding basic13,005,12811,148,40212,282,00410,551,503
Weighted average common shares outstanding diluted13,005,12811,148,40212,282,00410,551,503

ACXP Balance Sheet

2023-09-30
CONDENSED INTERIM BALANCE SHEETS - USD ($)
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS  
Cash$ 7,052,329$ 9,111,751
Prepaid Expenses105,722264,955
TOTAL ASSETS7,158,0519,376,706
CURRENT LIABILITIES  
Accounts Payable and Accrued Expenses3,223,3782,061,685
TOTAL CURRENT LIABILITIES3,223,3782,061,685
TOTAL LIABILITIES3,223,3782,061,685
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY  
Common Stock; $.001 par value, 200,000,000 shares authorized, 13,005,128 and 11,627,609 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively13,00511,628
Additional Paid-In Capital52,025,93145,944,478
Accumulated Deficit(48,104,263)(38,641,085)
TOTAL SHAREHOLDERS' EQUITY3,934,6737,315,021
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$ 7,158,051$ 9,376,706
ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.
 CEO
 WEBSITEwww.acurxpharma.com
 EMPLOYEES4

Acurx Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Acurx Pharmaceuticals, Inc.? What does ACXP stand for in stocks?

ACXP is the stock ticker symbol of Acurx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acurx Pharmaceuticals, Inc. (ACXP)?

As of Fri Mar 01 2024, market cap of Acurx Pharmaceuticals, Inc. is 41.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACXP stock?

You can check ACXP's fair value in chart for subscribers.

What is the fair value of ACXP stock?

You can check ACXP's fair value in chart for subscribers. The fair value of Acurx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acurx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACXP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acurx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACXP is over valued or under valued. Whether Acurx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Acurx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACXP.